An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Trial Profile

An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 01 Aug 2017 According to an AstraZeneca media release, the US FDA has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The FDA granted Breakthrough Therapy Designation based on the totality of clinical data from the acalabrutinib development program, including data from this trial.
    • 28 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Sep 2019.
    • 13 Oct 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top